Enjuanes L, Sola I, Izeta A, Sánchez-Morgado J M, González J M, Alonso S, Escors D, Sánchez C M
Department of Molecular and Cell Biology, CNB, CSIC, Cantoblanco, Madrid, Spain.
Adv Exp Med Biol. 1999;473:31-45. doi: 10.1007/978-1-4615-4143-1_3.
Historically, protection against virus infections has relied on the use of vaccines, but the induction of an immune response requires several days and in certain situations, like in newborn animals that may be infected at birth and die in a few days, there is not sufficient time to elicit a protective immune response. Immediate protection in new born could be provided either by vectors that express virus-interfering molecules in a tissue specific form, or by the production of animals expressing resistance to virus replication. The mucosal surface is the largest body surface susceptible to virus infection that can serve for virus entry. Then, it is of high interest to develop strategies to prevent infections of these areas. Virus growth can be interfered intracellularly, extracellularly or both. The antibodies neutralize virus intra- and extracellularly and their molecular biology is well known. In addition, antibodies efficiently neutralize viruses in the mucosal areas. The autonomy of antibody molecules in virus neutralization makes them functional in cells different from those that produce the antibodies and in the extracellular medium. These properties have identified antibodies as very useful molecules to be expressed by vectors or in transgenic animals to provide resistance to virus infection. A similar role could be played by antimicrobial peptides in the case of bacteria. Intracellular interference with virus growth (intracellular immunity) can be mediated by molecules of very different nature: (i) full length or single chain antibodies; (ii) mutant viral proteins that strongly interfere with the replication of the wild type virus (dominant-negative mutants); (iii) antisense RNA and ribozyme sequences; and (iv) the product of antiviral genes such as the Mx proteins. All these molecules inhibiting virus replication may be used to obtain transgenic animals with resistance to viral infection built in their genomes. We have developed two strategies to target into mucosal areas either antibodies to provide immediate protection, or antigens to elicit immune responses in the enteric or respiratory surfaces in order to prevent virus infection. One strategy is based on the development of expression vectors using coronavirus derived defective RNA minigenomes, and the other relies on the development of transgenic animals providing virus neutralizing antibodies in the milk during lactation. Two types of expression vectors are being engineered based on transmissible gastroenteritis coronavirus (TGEV) defective minigenomes. The first one is a helper virus dependent expression system and the second is based on self-replicating RNAs including the information required to encode the TGEV replicase. The minigenomes expressing the heterologous gene have been improved by using a two-step amplification system based on cytomegalovirus (CMV) and viral promoters. Expression levels around 5 micrograms per 10(6) cells were obtained. The engineered minigenomes will be useful to understand the mechanism of coronavirus replication and for the tissue specific expression of antigen, antibody or virus interfering molecules. To protect from viral infections of the enteric tract, transgenic animals secreting virus neutralizing recombinant antibodies in the milk during lactation have been developed. Neutralizing antibodies with isotypes IgG1 or IgA were produced in the milk with titers of 10(6) in RIA that reduced virus infectivity by one million-fold. The recombinant antibodies recognized a conserved epitope apparently essential for virus replication. Antibody expression levels were transgene transgene copy number independent and were related to the transgene integration site. This strategy may be of general use since it could be applied to protect newborn animals against infections of the enteric tract by viruses or bacteria for which a protective MAb has been identified. Alternatively, the same strategy could be used to target the expression of antibio
从历史上看,预防病毒感染一直依赖于疫苗的使用,但诱导免疫反应需要几天时间,在某些情况下,比如新生动物可能在出生时就被感染并在几天内死亡,没有足够的时间引发保护性免疫反应。新生动物的即时保护可以通过以组织特异性形式表达病毒干扰分子的载体来提供,或者通过培育对病毒复制具有抗性的动物来实现。黏膜表面是最易受病毒感染的身体表面,可作为病毒进入的途径。因此,开发预防这些部位感染的策略具有很高的研究价值。病毒生长可在细胞内、细胞外或两者同时受到干扰。抗体可在细胞内和细胞外中和病毒,其分子生物学特性已为人熟知。此外,抗体能有效中和黏膜部位的病毒。抗体分子在病毒中和过程中的自主性使其在不同于产生抗体的细胞以及细胞外介质中发挥作用。这些特性已确定抗体是非常有用的分子,可通过载体或在转基因动物中表达以提供对病毒感染的抗性。抗菌肽在对抗细菌方面也可发挥类似作用。细胞内对病毒生长的干扰(细胞内免疫)可由性质非常不同的分子介导:(i)全长或单链抗体;(ii)强烈干扰野生型病毒复制的突变病毒蛋白(显性负突变体);(iii)反义RNA和核酶序列;(iv)抗病毒基因的产物,如Mx蛋白。所有这些抑制病毒复制的分子都可用于培育基因组中内置有抗病毒感染能力的转基因动物。我们已开发出两种策略,将抗体靶向黏膜区域以提供即时保护,或将抗原靶向肠道或呼吸道表面以引发免疫反应,从而预防病毒感染。一种策略基于利用冠状病毒衍生的缺陷RNA微型基因组开发表达载体,另一种则依赖于培育在哺乳期乳汁中提供病毒中和抗体的转基因动物。基于传染性胃肠炎冠状病毒(TGEV)缺陷微型基因组构建了两种类型的表达载体。第一种是依赖辅助病毒的表达系统,第二种基于自我复制RNA,包含编码TGEV复制酶所需的信息。通过使用基于巨细胞病毒(CMV)和病毒启动子的两步扩增系统,表达异源基因的微型基因组得到了改进。每10^6个细胞可获得约5微克的表达水平。构建的微型基因组将有助于了解冠状病毒复制机制,并用于抗原、抗体或病毒干扰分子的组织特异性表达。为了预防肠道病毒感染,已培育出在哺乳期乳汁中分泌病毒中和重组抗体的转基因动物。乳汁中产生的具有IgG1或IgA同种型的中和抗体,在放射免疫分析中的效价为10^6,可使病毒感染性降低一百万倍。重组抗体识别一个显然对病毒复制至关重要的保守表位。抗体表达水平与转基因拷贝数无关,而与转基因整合位点有关。该策略可能具有广泛用途,因为它可用于保护新生动物免受已鉴定出保护性单克隆抗体的病毒或细菌引起的肠道感染。或者,相同的策略可用于靶向抗体的表达……